Genentech has revealed negative results from the IMblaze370 study, a Phase III trial investigating Tecentriq (atezolizumab) in combination with Cotellic (cobimetinib) to treat patients with heavily pre-treated, locally advanced or metastatic colorectal cancer (CRC).
The multi-centre, open-label, three-arm, randomised trial enrolled 363 people with difficult-to-treat locally advanced or metastatic colorectal cancer who have received at least two prior regimens of chemotherapy for metastatic disease.
It also compared a standard of care therapy regorafenib with Cotellicplus Tecentriq and Tecentriq monotherapy.
During the trial, patients were randomised at 2:1:1 ratio to receive Tecentriq plus Cotellic, or Tecentriq, or Regorafenib.
Patients in the combination arm received Cotellicon days one to 21 plus Tecentriq on day one and day 15 in a 28-day cycle.
Participants in the monotherapy arm received Tecentriq on day one of each 21-day cycle, while those in the control arm received regorafenib on days one to 21 in a 28-day cycle, until loss of clinical benefit.
The trial’s primary endpoint was overall survival, while key secondary endpoints comprised progression-free survival (PFS), overall response rate (ORR) and duration of response (DoR).
The trial was unable to meet its primary endpoint of overall survival (OS) compared to regorafenib.
Genentech chief medical officer and global product development head Sandra Horning said: “While these results are not what we hoped for, we remain committed to applying our deep experience to develop medicines that will improve outcomes for people living with gastrointestinal cancers.
“In particular, we have a number of studies evaluating medicines in colorectal cancer that could play an important role in the treatment of people with this disease in the future.”
Genentech expects to further evaluate the results from IMblaze370 and present them at an upcoming medical meeting.